Speed
Ready in the first days of an outbreak — not the first year. Antivirals close the deadly gap before vaccines arrive.


Building out our antiviral toolkit proactively rather than reactively
What is ViRx@Stanford
Antivirals ready before the next outbreak — not after it.
BE READI !
Stanford BiosEcuRity & PandEmic PrepAreDness Initiative
The Threat
Each pandemic has cost millions of lives and trillions in economic damage. The world has responded reactively, every time.
Next Unknown
Are we ready?
The Vision
Healthy families. Thriving communities. Economies that never again grind to a halt. This is the future ViRx@Stanford is building — one where humanity meets the next virus from a position of strength.

Why Antivirals
Antivirals are the fast, flexible first line of defense — deployable in the critical early window before a vaccine can ever exist.
Ready in the first days of an outbreak — not the first year. Antivirals close the deadly gap before vaccines arrive.
Broad-spectrum candidates can work across virus families, including threats we haven’t seen yet.
When a new virus emerges, antivirals are what stand between an outbreak and a pandemic.
Our Unique Solution
ViRx@Stanford doesn’t bet on a single drug. We combine three complementary antiviral strategies — SyneRx sets the example.


Establish proactive, long-term partnerships with companies developing next-generation biodefense countermeasures.
INVESTMENT & ACCESS MODEL
Advanced procurement of countermeasures
Priority purchase rights for future doses
Direct investment in companies
Investment in scalable manufacturing
Seats on government advisory committees
Annual convening of biodefense leaders
Lab space, personnel and infrastructure
Hosting high-potential companies


Leadership
World-class scientists and operators with a proven track record of translating discovery into real-world impact.
Advisory Board

CEO, Moderna Therapeutics

Professor of Medicine & Molecular Pharmacology, Emeritus · Stanford University

Division of Global Health Equity · Brigham and Women's Hospital

CEO & Chairperson, Ansun BioPharma

Emeritus Associate Dean of Research · Stanford University School of Medicine

Immediate Past Chair, Biotechnology Innovation Organization (BIO) · Former President & CEO, Global Blood Therapeutics

Chief Strategy Officer & Director, Perpetuals.com Ltd.

Professor & Chair, Microbiology · Mount Sinai School of Medicine

Professor of Virology, Rockefeller University · Nobel Laureate

Professor of Pathology and Medicine (Active Emeritus), U.C. San Diego

Professor of Microbiology, Stanford Univ.; Natl. Security Task Force on Pandemic

Program Officer, Coefficient Giving, National Academy of Sciences

Co-Founder and Managing Director of SunasiAI

Professor/Co-Director, Pediatric Infectious Diseases · UAB
Global Impact
Collaborating hubs across continents, anywhere a threat can emerge

Funding & Support





Partnership
Partner at the scale of the problem. Each level unlocks a distinct piece of the global antiviral defense system.
$10M+
Fund a full antiviral discovery program against a priority threat.
$50M+
Build out a platform pillar — AI engine, preclinical, or clinical translation.
$100M+
Name and endow the defense system. Define humanity’s antiviral future.
Your Legacy
Let's talk about what your partnership can make possible.